Search

Diclazuril, a new anticoccidial drug, was tested for its efficacy against Eimeria dispersa in turkeys. A dose-titration study indicated that diclazuril at dosages of 0.5, 1, and 2 ppm in the feed was highly effective in terms of weight gain and suppression of lesions, abnormal droppings, and oocyst shedding.

Diclazuril, a new anticoccidial drug, was tested in young pheasants artificially infected with the three most common pathogenic species of Eimeria, E colchici, E duodenalis and E phasiani. In two replicate experiments each with 40 birds the mortalities in the infected controls were 50 and 25 per cent. Diclazuril was administered in the feed at dose levels of 1, 2 and 4 ppm from the day before the inoculation of coccidia until the end of the test on day 6 after infection. The 1 ppm dose failed to inhibit the development of the parasite completely, as was shown by a reduction of the weight gain of the birds and the output of a small number of oocysts. Diclazuril at 2 or 4 ppm adequately controlled the infection, with weight gains similar to those of the uninfected controls. At all dose levels, mortality, intestinal lesions and diarrhoea were prevented.

Diclazuril is a benzeneacetonitrile showing great promise as a broad-spectrum anticoccidial agent for chickens, turkeys, and rabbits. The high anticoccidial activity of diclazuril in chickens, as first reported in dose-titration studies and battery trials, was confirmed in three floor-pen trials. The efficacy was demonstrated against six major pathogenic species of Eimeria after artificial infection with one or more species. The experimental data indicated that diclazuril, at dose levels of .5, .75, 1, and 2 ppm, had a high anticoccidial activity in terms of preventing mortality, suppressing or reducing lesion scores, and allowing for normal weight gains as well as productivity. The performances obtained with diclazuril was generally comparable with that of salinomycin at 60 ppm and that of lasalocid at 90 ppm.

Diclazuril, a new anticoccidial drug, was tested for its efficacy in turkeys against single Eimeria infections. Dose-titration studies indicated that diclazuril at dosages of 0.1, 0.5, 1, and 2 ppm was highly effective against the major pathogenic species-E. adenoeides, E. gallopavonis, and E. meleagrimitis-in terms of weight gain and suppression of lesions, abnormal droppings, and oocyst shedding.

The efficacy of diclazuril against intestinal and hepatic coccidiosis was studied in artificially infected rabbits. Prophylaxis against intestinal coccidiosis was evaluated using a mixed infection of Eimeria intestinalis, Eimeria magna and Eimeria perforans. Continuous medication in the feed at 1 p.p.m. was 100% effective in reducing oocyst output and faecal scores, and weight gain and feed efficiency were normal. Hepatic coccidiosis induced by Eimeria stiedai was prevented at 0.5 and 1 p.p.m. as shown by negative oocyst counts, normal liver weight, absence of liver lesions, and normal body-weight gain and feed efficiency. Medication at 1 p.p.m. for 7 consecutive days during the prepatent phase of hepatic coccidiosis resulted in large reductions in oocyst counts and lesion scores with a normal liver weight and growth performance. Diclazuril at 1 p.p.m. in the feed prevented both intestinal and hepatic coccidiosis in rabbits and can be advocated for safe mass medication.

Battery trials have confirmed the broad spectrum anticoccidial activity of diclazuril as previously reported in dose titration studies. The advocated dose level of 1 ppm in the diet demonstrated excellent activity against the economically most important Eimeria species. At this dose level, body weight gains were comparable to those of uninfected, unmedicated controls and the oocyst production was negative in most species. Lesion scores and dropping scores were nil or highly reduced. An E. maxima-147 strain, less sensitive to ionophores, also responded well to diclazuril. It was concluded that diclazuril is a promising anticoccidial for the control of all species of coccidia that cause losses to the poultry industry.

Diclazuril, a new anticoccidial drug, was tested in poultry against six Eimeria species either in single species infections in dose titration studies or in mixed species infections in floor pen trials. The dose titration studies in cockerels indicated that diclazuril at dosages of 10, 5, 1, and .5 ppm was highly active against all major pathogenic species: E. tenella, E. acervulina, E. necatrix, E. brunetti, E. maxima, and E. mitis and effective in terms of weight gain and suppression of mortality, dropping scores, and oocyst counts. In two floor pen trials diclazuril was fed for 6 wk to broiler chickens experimentally infected either with E. tenella and E. acervulina or with E. necatrix and E. brunetti. Dose levels of 10, 5, and 1 ppm suppressed mortality and lesion scores. Even at 1 ppm the mean terminal body weight, feed conversion, and productivity index of treated birds were comparable to results for the uninfected, unmediated controls. In these pilot studies, involving 1,020 Hisex and 1,000 Hubbard broiler chickens, it has been demonstrated that diclazuril at the dose level of 1 ppm in the diet is an excellent anticoccidial without any adverse effects.

Racing pigeons were artificially infected with a mixed inoculum of Eimeria labbeana (85 per cent) and E columbarum (15 per cent) and treated orally with 2.5 mg clazuril either on day 1, 2, 3, 4, 5, 6 or 7 after infection. The impact of the treatment on the different developmental stages was evaluated by oocyst output and by histological examination of the duodenum and jejunum. The life cycle always became completely interrupted, but maximal effects were noted when treatment was given on day 4, 5 or 6 after infection. Treatment during patency completely interrupted oocyst excretion within three days after dosing. Degenerative changes in schizonts and gametocytes were always observed. The histology revealed a reduced number and abnormal structure of developing merozoites; a ballooned aspect and presence of numerous small vacuoles in the microgametocytes; the absence of typical wall-forming bodies in macrogametocytes and a complete absence of oocysts. It is concluded that clazuril has a coccidiocidal effect on the asexual and sexual developmental stages of both Eimeria species, resulting in a complete interruption of the life cycle.

The anticoccidial efficacy of diclazuril was studied in rabbits artificially infected with Eimeria flavescens, Eimeria intestinalis, Eimeria magna and Eimeria perforans. Continuous administration at 1 and 2 ppm in pelleted feed proved to be highly efficacious in controlling oocyst output and faecal scores. The weight gain was comparable and the feed efficiency slightly improved compared with the non-infected, non-medicated controls, and clinical signs were fully prevented. Medication of rabbits at 0.5 ppm also provided a significant improvement in all parameters compared with the infected, non-medicated controls. In order to obtain 100% effectiveness in the control of intestinal coccidiosis in rabbits, continuous medication at 1 ppm is recommended.

Diclazuril, a new anticoccidial drug, was tested for its efficacy in turkeys against mixed Eimeria infections. A floor-pen trial indicated that diclazuril at dosages of 0.5 ppm and 1 ppm in the feed was highly effective against the major pathogenic species E. adenoeides, E. gallopavonis, and E. meleagrimitis in suppressing intestinal and cecal lesions and oocyst shedding. Weight gain and feed conversion improved, particularly at 1 ppm.